Japan SNP (Single Nucleotide Polymorphism) Market Insight
Japan SNP market is growing at a 12.93% CAGR, due to rising adoption of genomic research, personalized medicine, precision diagnostics, and increasing use of SNP genotyping technologies in healthcare and biotechnology applications.
Japan SNP (Single Nucleotide Polymorphism) Market Insights Forecasts to 2035
- The Japan SNP (Single Nucleotide Polymorphism) Market Size Was Estimated at USD 780.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.93% from 2025 to 2035
- The Japan SNP (Single Nucleotide Polymorphism) Market Size is Expected to Reach USD 2632.2 Million by 2035
Notable Insights for Japan SNP (Single Nucleotide Polymorphism) Market
- By technology, the PCR-based SNP genotyping segment dominated the market, accounting for over 40%–45% share, driven by high accuracy, cost efficiency, and widespread clinical adoption
- By application, the pharmacogenomics and personalized medicine segment is expected to witness the fastest growth, supported by increasing precision medicine initiatives, with growth projected at over 13%–15% CAGR
- Approximately 70%–75% of demand is driven by pharmaceutical, biotechnology, and research laboratories, where SNP analysis supports disease diagnostics, drug discovery, and genetic testing. Additionally, pharmaceutical & biotechnology companies accounted for over 51% share globally in 2024
- Government genomic research initiatives and increasing investment in precision healthcare are strengthening the Japan SNP Market, while Japan’s advanced biotechnology sector continues supporting large-scale genomic analysis adoption
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan SNP (Single Nucleotide Polymorphism) market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan SNP (Single Nucleotide Polymorphism) Market
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc.
- Beckman Coulter Inc.
- Danaher Corporation
- Others
Recent Developments:
- In March 2026, biotechnology companies expanded AI-integrated SNP genotyping platforms to improve genomic analysis speed and precision medicine research capabilities
- In October 2025, healthcare and research institutions in Japan increased investment in next-generation sequencing (NGS) and SNP analysis technologies for disease diagnostics and pharmacogenomics applications
Market Segmentation:
Japan SNP (Single Nucleotide Polymorphism) Market, By Technology
- PCR-Based Genotyping
- Sequencing-Based Genotyping
- Microarray-Based Genotyping
Japan SNP (Single Nucleotide Polymorphism) Market, By Application
- Pharmacogenomics
- Genetic Testing
- Disease Diagnostics
- Agricultural Biotechnology
Japan SNP (Single Nucleotide Polymorphism) Market, By End User
- Pharmaceutical & Biotechnology Companies
- Research Laboratories
- Clinical Laboratories
- Academic Institutes
Expert Views:
The Japan SNP Market is poised for strong growth, driven by increasing genomic research and rising demand for personalized medicine solutions. Experts highlight that PCR-based SNP genotyping will dominate due to accuracy and affordability, while AI-enabled genomic analytics and pharmacogenomics applications will witness the fastest growth, ensuring expansion of precision healthcare in Japan.